Objectives To report the results of a national survey aimed at quantifying the current level of diffusion of Levodopa/carbidopa intestinal gel (LCIG) in Italy. Methods Sixty Parkinson's Disease (PD) specialists in Italy were invited to complete a survey covering issues on clinical and practical aspects of LCIG therapy. Results Clinical features of 905 patients were collected retrospectively. The majority of centres reported the use of a multidisciplinary team, biochemistry testing, neurophysiological and neuropsychological tests before and after treatment, in addition to caregivers’ training and patient's follow as outpatients. Most centres (60%) used internal guidelines for patient selection. The overall rate of adverse events was 55.1%. Weight loss, chronic polyneuropathy and stoma infection were the most frequently reported. 40% of centres used replacement therapy with Vitamin B12 and Folic acid from the start of LCIG and continued this for the duration of treatment. The rate of discontinuation was of 25.7% overall, with 9.5% of cases occurring in the first year. The main causes of withdrawal were device-related complications, disease progression (comorbidity, severe dementia) and caregiver and/or patient dissatisfaction. Conclusions In Italy LCIG infusion is managed in a uniform manner at a clinical, practical and organizational level even though the selection criteria are not standardized through the country. The high percentage of patients remaining on treatment in the short- and long-term follow-up confirms effectiveness of treatment, careful follow-up, and appropriate patient and caregivers training

Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up / Sensi, Mariachiara; Cossu, Giovanni; Mancini, Francesca; Pilleri, Manuela; Zibetti, Maurizio; Modugno, Nicola; Quatrale, Rocco; Tamma, Filippo; Antonini, Angelo; Aguggia, Marco; Amboni, Marianna; Arca, Roberta; Bartolomei, Luigi; Bonetto, Nicola; Calandra Buonaura, Giovanna; Bove, Francesco; Calandrella, Daniela; Canesi, Margherita; Cannas, Antonino; Capecci, Marianna; Caputo, Elena; Ceravolo, MARIA GABRIELLA; Ceravolo, Roberto; Cerrone, Gloria; Coletti Moja, Mario; Comi, Cristoforo; Cortelli, Pietro; D'Antonio, Paola; Dematteis, Francesca; Di Lazzaro, Vincenzo; Eleopra, Roberto; Fabbrini, Giovanni; Fichera, Mario; Grassi, Enrico; Guido, Marco; Gusmaroli, Graziano; Latorre, Anna; Malaguti, Maria Chiara; Marano, Massimo; Marano, Pietro; Marconi, Roberto; Mazzucchi, Sonia; Meco, Giuseppe; Minafra, Brigida; Morgante, Francesca; Pacchetti, Claudio; Pierantozzi, Mariangela; Pontieri, Francesco E.; Riboldazzi, Giulio; Ricchi, Valeria; Ricchieri, Gianluigi; Rinaldo, Sara; Rispoli, Vittorio; Rossi, Simone; Rubino, Alfonso; Russo, Antonio; Saddi, Maria Valeria; Stefani, Alessandro; Simoni, Simone; Solla, Paolo; Tambasco, Nicola; Tamburin, Stefano; Tessitore, Alessandro; Torre, Elena; Ulivelli, Monica; Vita, Maria Gabriella; Volonté, Maria Antonietta. - In: PARKINSONISM & RELATED DISORDERS. - ISSN 1353-8020. - STAMPA. - 38:(2017), pp. 90-92. [10.1016/j.parkreldis.2017.02.020]

Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up

CAPECCI, MARIANNA;CERAVOLO, MARIA GABRIELLA;
2017-01-01

Abstract

Objectives To report the results of a national survey aimed at quantifying the current level of diffusion of Levodopa/carbidopa intestinal gel (LCIG) in Italy. Methods Sixty Parkinson's Disease (PD) specialists in Italy were invited to complete a survey covering issues on clinical and practical aspects of LCIG therapy. Results Clinical features of 905 patients were collected retrospectively. The majority of centres reported the use of a multidisciplinary team, biochemistry testing, neurophysiological and neuropsychological tests before and after treatment, in addition to caregivers’ training and patient's follow as outpatients. Most centres (60%) used internal guidelines for patient selection. The overall rate of adverse events was 55.1%. Weight loss, chronic polyneuropathy and stoma infection were the most frequently reported. 40% of centres used replacement therapy with Vitamin B12 and Folic acid from the start of LCIG and continued this for the duration of treatment. The rate of discontinuation was of 25.7% overall, with 9.5% of cases occurring in the first year. The main causes of withdrawal were device-related complications, disease progression (comorbidity, severe dementia) and caregiver and/or patient dissatisfaction. Conclusions In Italy LCIG infusion is managed in a uniform manner at a clinical, practical and organizational level even though the selection criteria are not standardized through the country. The high percentage of patients remaining on treatment in the short- and long-term follow-up confirms effectiveness of treatment, careful follow-up, and appropriate patient and caregivers training
2017
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11566/249923
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 17
  • Scopus 45
  • ???jsp.display-item.citation.isi??? 42
social impact